MIMEDX Announces Launch of EPIEFFECT™
September 26 2023 - 7:00AM
MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today
announced the launch of EPIEFFECT™, the Company’s latest addition
to its portfolio of AWC solutions.
EPIEFFECT expands the Company’s core AWC
offering for clinicians treating acute and chronic, hard-to-heal
wounds such as diabetic foot ulcers (“DFUs”) and venous leg ulcers
(“VLUs”), among other common conditions. EPIEFFECT offers a thick,
tri-layer configuration that is suitable for securing the graft in
place with sutures. In addition, its product attributes and
handling characteristics make it a preferable treatment option for
deep or tunneling wounds.
“We are delighted to introduce another
innovation in the Wound & Surgical marketplace,” said Joseph H.
Capper, MIMEDX Chief Executive Officer. “EPIEFFECT provides a
thick, tri-layer option to our customers, including those in the
private physician office setting. Our approach is to provide the
most clinically-effective and evidence-based products possible in
the markets we serve, that are designed to meet specific customer
demand and use cases. We believe EPIEFFECT effectively addresses
the need for a robust allograft solution, available in an
assortment of sizes, to address complex wounds in-office before
hospital-based intervention may be required.”
Dr. Christopher Gill, D.P.M., M.S., a podiatrist
at the McLaren Bay Region Wound Care Center in Bay City, Michigan
added, “I am very excited to incorporate EPIEFFECT into my wound
care treatment strategy. As a longtime advocate of EPIFIX, I have
seen firsthand how MIMEDX’s product portfolio can be ideally suited
for a variety of patients in need of an allograft solution.
Specifically, I appreciate the level of robust scientific and
clinical evidence that supports the development of MIMEDX’s product
offerings, and with EPIEFFECT, I look forward to having another
innovative option for a wide range of wound types.”
Mr. Capper continued, “As we have been preparing
for its launch, customer anticipation for EPIEFFECT is high and we
look forward to seeing how this product can help patients with
chronic and hard-to-heal wounds.”
About EPIEFFECTEPIEFFECT is a
lyophilized human placental-based allograft consisting of amnion
and chorion membranes, while also retaining the intermediate layer.
EPIEFFECT is intended for use as a barrier, to provide a protective
environment in acute and chronic wounds; the tissue provides a
biocompatible human extracellular matrix (“ECM”) and contains more
than 300 regulatory proteins. EPIEFFECT is available in a variety
of size options ranging from 6 cm2 to 49 cm2. Additionally, like
EPIFIX® and EPICORD®, EPIEFFECT is listed on the Medicare Part B
Average Sales Price File, effective October 1, 2023. To learn more,
please visit https://www.mimedx.com/epieffect/.
About MIMEDXMIMEDX is a pioneer
and leader focused on helping humans heal. With more than a decade
of helping clinicians manage chronic and other hard-to-heal wounds,
MIMEDX is dedicated to providing a leading portfolio of products
for applications in the wound care, burn, and surgical sectors of
healthcare. The Company’s vision is to be the leading global
provider of healing solutions through relentless innovation to
restore quality of life. For additional information, please visit
www.mimedx.com.
Contact:Matt NotarianniInvestor
Relations470-304-7291mnotarianni@mimedx.com
MiMedx (NASDAQ:MDXG)
Historical Stock Chart
From Apr 2024 to May 2024
MiMedx (NASDAQ:MDXG)
Historical Stock Chart
From May 2023 to May 2024